Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > AACR

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Mar 30, 2022 4:04pm

81 Views

Post# 34560366

RE:AACR

I have not seen any announcement on when the AGM is yet. Pre covid it was typcially in mid-May

Biobob wrote:
So we have AACR coming up on April 11 and Q2 around mid April and then AGM on April 10... now it's no news sub 3$ to celebrate the printing of March statements.. I guess they don't care because the Cancer data will solve everything soon I hope... with growing sales of 80M they can refinance the debenture without giving away shares, so selling here is plain stupidity even if you hate everything about the company.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China